Showing results (111-120 of 277) with videos related to
Sort By:
Pageof 28
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2010
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2Joseph Paul Eder, Geoffrey I Shapiro, Leonard J Appleman, et al.DNA Repair|September 10, 2019
Functional profiling of nucleotide Excision repair in breast cancerAnne S Rajkumar-Calkins, Raphael Szalat, Matija Dreze, et al.JNCI Cancer Spectrum|April 25, 2020
An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 PatientsNicole G Chau, Clement Ma, Kristina Danga, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2013
Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumorsLeena Gandhi, Rastislav Bahleda, Sara M Tolaney, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2014
A Phase I, dose-finding study in patients with advanced solid malignancies of the oral γ-secretase inhibitor PF-03084014Wells A Messersmith, Geoffrey I Shapiro, James M Cleary, et al.The Oncologist|March 8, 2018
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced CancersAnthony Tolcher, Keith Flaherty, Geoffrey I Shapiro, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumorsCristiana Sessa, Geoffrey I Shapiro, Kapil N Bhalla, et al.Cancer Research|August 19, 2015
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase InhibitionMargaret Soucheray, Marzia Capelletti, Inés Pulido, et al.Cancer|March 11, 2026
Targeted therapy for DNA damage response and homologous recombination repair defects: The Olaparib Combinations trialDeborah B Doroshow, Geoffrey I Shapiro, Khanh Do, et al.Investigational New Drugs|July 1, 2015
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancerSara M Tolaney, Sally Tan, Hao Guo, et al.Pageof 28